Discover how identifying a diverse range of high-affinity SARS-CoV-2 Spike/RBD monoclonal antibodies can be achieved within 24 hours to accelerate therapeutic, diagnostic, vaccine, and basic research immunoassay development!
Accelerated discovery of high-affinity, highly diverse SARS-CoV-2 Spike/RBD rabbit mAbs via single B cell screening within 24 hours
•
Larger antibody diversity achieved through single B cell screening compared to hybridoma technology
•
Diverse mAbs that recognize multiple unique epitopes are critical for optimal immunoassay development, including sandwich ELISA to a sensitivity of 20 pg/ml
